How does PCV20 compare to PCV13 and PPSV23?
PCV20, which has been registered for use with the HSA since 30 November 2022, provides a broader coverage of pneumococcal strains. Studies have shown that the vaccine induces antibody levels comparable to those induced by PCV13 or PPSV23. In addition, vaccination with PCV20 can be completed as a single dose regimen.
Need more help?
Get in touch